23rd Mar 2016 17:07
GW Pharmaceuticals Announces Results of Annual General Meeting
Cambridge, UK, 23 March 2016: GW Pharmaceuticals plc (AIM: GWP, NASDAQ: GWPH or the "Company") hereby provides notification that, at the Annual General Meeting of the Company held earlier today, all the resolutions set out in the Notice of Meeting sent to shareholders were duly proposed and passed.
All resolutions were approved on a show of hands. Details of the proxy votes received in relation to each of the resolutions (which are more particularly described in the Notice of General Meeting) are as follows:
For1, 2 | Against1 | Withheld | |||
Ordinary resolutions | |||||
Resolution 1 - To receive, consider and adopt the Directors' and Auditors' Reports and Statement of Accounts for the year ended 30 September 2016 | 224,039,382 | 99.80% | 450,875 | 0.20% | 285,420 |
Resolution 2 - To approve the Directors' Remuneration Report | 220,340,924 | 98.19% | 4,051,711 | 1.81% | 383,042 |
Resolution 3 - To re-elect Adam George as a Director | 199,151,339 | 88.76% | 25,229,611 | 11.24% | 394,727 |
Resolution 4 - To re-elect James Noble as a Director | 219,904,356 | 98.00% | 4,491,570 | 2.00% | 379,751 |
Resolution 5 - To re-elect Christopher Tovey as a Director | 199,224,442 | 88.78% | 25,176,764 | 11.22% | 374,471 |
Resolution 6 - To re-elect Julian Gangolli as a Director | 193,476,666 | 86.22% | 30,921,912 | 13.78% | 377,099 |
Resolution 7 - To re-appoint Deloitte LLP as Auditor | 224,411,844 | 99.90% | 222,865 | 0.10% | 140,968 |
Resolution 8 - To authorise the Directors to determine the Auditor's remuneration | 224,066,168 | 99.79% | 478,704 | 0.21% | 227,680 |
Resolution 9 - To authorize an increase in the aggregate annual limit on the fees payable to Directors to £1,000,000 | 222,644,542 | 99.20% | 1,794,438 | 0.80% | 333,570 |
Special Resolutions (requires 75% majority) | |||||
Resolution 10 - That the Directors be authorised to disapply pre-emption rights for cash issues of up to 20% of the Company's issued share capital | 181,835,330 | 81.02% | 42,586,722 | 18.98% | 353,625 |
1 A vote withheld is not a vote in law and, is not counted in the calculation of the votes for or against a resolution. Therefore, the percentage of votes cast excludes withheld votes.
2 Proxy forms which gave the Chairman or other officer of the Company discretion have been included in the "For" total.
On 23 March 2016, there were 262,717,686 GW Pharmaceuticals plc ordinary shares in issue. Shareholders are entitled to one vote per share held.
The full text of each resolution passed at the Annual General Meeting held earlier today, Wednesday 23 March 2016, is set out in the Notice of Annual General Meeting which is available for viewing on the Company's website at www.gwpharm.com.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
For further information, please contact:
GW Pharmaceuticals plc | |
Adam George, Company Secretary | +44 (0)1980 557 000 |
Peel Hunt LLP (UK NOMAD) | |
James Steel | +44 20 7418 8900 |
Related Shares:
GWP.L